RxDoctor Payments Data

Shahi Prabhakaran

Nurse Practitioner · Rockville, MDNPI 1588783567

Payments from drug & device makers

$379in general payments, 2019–2025

Across 19 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$124
  • GSK$70
  • Orexo US, Inc.$59
  • Exact Sciences$34
  • Novo Nordisk$24
  • Phathom Pharmaceuticals, Inc.$24
  • plus $44 from 3 others

What the payments were for

  • Food & beverage$379100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$379 in reported general payments places this provider in the 75th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland

Medicare billing

Part B allowed, 2024
$64,590
Medicare patients
161
Services billed
742

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$71,533
OzempicSemaglutide45$49,825
JardianceEmpagliflozin41$43,293
SuboxoneBuprenorphine Hcl/Naloxone Hcl72$40,222
TrulicityDulaglutide28$29,595
JanuviaSitagliptin Phosphate28$25,662
EliquisApixaban25$24,495
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl106$21,513
FarxigaDapagliflozin Propanediol17$20,254
MyrbetriqMirabegron13$10,630
KerendiaFinerenone12$8,504
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$7,496
LinzessLinaclotide12$6,948
Albuterol Sulfate HfaAlbuterol Sulfate158$4,318
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$3,958

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta$70$79,02987 claims
Novo NordiskOzempic$24$49,82545 claims
Lilly USA, LLCTrulicity$16$29,59528 claims
PfizerEliquis$13$24,49525 claims
AstraZenecaFarxiga$124$20,25417 claims
AbbVieLinzess$15$6,94812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,562 nurse practitioner providers in Maryland.

Other nurse practitioner in Rockville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →